Cohort study
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients
- Retrospective cohort study
- multicentre registry
Authors' conclusion
Chimeric antigen receptor T-cell therapy recipients who experience SCE have higher overall mortality and NRM and higher peak levels of IL-6, CRP, ferritin, and troponin.
Study context
- Population
- Patients receiving anti-CD19 CAR-T108 died
- Participants
- 202 patients
- Exposure
- Severe cardiovascular events (SCE) vs no SCE after CAR-T
- SCEn = 33
- Outcome
- Overall mortality
- Follow-up
- Median 297 (IQR 104-647) days
Main finding
As reported in the abstract
Hazard ratio
2.8
95% CI 1.6–4.7
SCE vs No SCE
HR 2.8 (95% CI 1.6–4.7)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Non-relapse mortality · adjusted for cancer burden | 3.5 (1.4–8.8) | |
| 0.10.31310Hazard ratio (log scale) |
Overall mortality and non-relapse mortality (NRM), whole cohort (Kaplan-Meier / cumulative incidence) · day 100 and 1 year
- Overall mortality, day 100
- 18%
- Overall mortality, 1 year
- 43%
- NRM, day 100
- 3.5%
- NRM, 1 year
- 6.7%
Biomarkers
- SCE: higher peak IL-6, C-reactive protein (CRP), ferritin and troponin
- Died: higher peak IL-6 and ferritin after CAR-T infusion
- Died vs survived: similar age, sex and prior anthracycline use
Original publication
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. Published 20 March 2023. doi:10.1093/eurheartj/ehad117
Summarised from the published abstract; every number is checked against it